J&J: EU marketing authorization application for Rybrevant -December 22, 2023 at 09:01 am EST

Johnson & Johnson announces that it has submitted a marketing authorization application to the European Medicines Agency seeking approval of lazertinib + Rybrevant for the first-line treatment of...

Related Keywords

Catherine Taylor ,European Medicines Agency ,Johnson ,Vice President Medical Affairs ,Therapeutic Area Strategy ,Markets ,